2 in 5 adults with severe kidney disease don’t know they have it.

Measuring a patient’s eGFR levels alone is not sufficient to determine if they have chronic kidney disease (CKD) and/or type 2 diabetes (T2D). UACR levels must also be measured.

And multiple clinical guidelines recommend a nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) such as KERENDIA® for the management of CKD and T2D in adults.

Bayer® wanted us to convey these important messages to HCPs nationwide.

So we did, with the utmost sense of urgency.